Stock Analiz

Silexion Therapeutics Corp SLXN

Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026

$1.98Market cap $1M
Open the interactive analysis →

Silexion Therapeutics Corp (SLXN) is a healthcare company listed in the US with a market value of about $1M. In the twelve months to September 30, 2026 it had revenue of $133000 and net income of -$13M, a net margin of -9946.6%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -299%.

About Silexion Therapeutics

Silexion Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances). It was profitable in 0 of the last 3 years in our data. It spends 4606% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S9.7
P/B0.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-913.0%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)453.6%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-23340.0%
ROIC (5-yr avg.)-299.2%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 3 years

Fiscal yearTTM202520242023
Revenue$133000$155000$28000$153000
Net income-$13M-$12M-$17M-$5M
Free cash flow-$12M-$11M-$8M-$5M
EPS (diluted)$-19.90$17.92$789.88$1325.46
Net margin-9946.6%-7685.2%-58996.4%-3338.6%
ROIC—-299.2%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 1 analysts is $120.00, 5961% above the current price; targets range from $120.00 to $120.00; the consensus rating is “none”; expected EPS is $-112.80 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Silexion Therapeutics pay a dividend?

Not currently.

Is Silexion Therapeutics a good stock to buy?

We do not give buy or sell advice. Silexion Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.